BIO-TECHNE Corp
TECH- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000842023
No open-market purchases or sales by BIO-TECHNE Corp insiders were filed in the last 90 days; 601 institutions reported holding it in 13F filings for Q2 2026, worth $12.3B in total; 3 superinvestors hold it, including Maverick Capital and Weitz Investment Management.
Key figures
- Market capClose on Nov 10, 2026
- $11.4B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +17 vs. previous quarter
- 601
- 13F valueReported value at the end of Q2 2026
- $12.3B
- Superinvestors holdingAt the end of Q2 2026
- 3
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2026
- $1.22B
- −0.4% year over year
- Net income, FY2026
- $181.9M
- +147.8% year over year
- Free cash flow, FY2026
- $263.2M
- +2.6% year over year
- Revenue, Q1 FY2027
- $299.7M
- +4.6% year over year
Revenue flow, FY2026
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 7.55M
- Shares sold short
- Change
- +167.2K
- +2.3% vs. previous
- Days to cover
- 2.88
- At average daily volume
Superinvestors holding TECH, Q2 2026
Go to the superinvestors tab3 superinvestors report holding BIO-TECHNE Corp on Form 13F. Percentages are the stock's share of each portfolio.
Weitz Investment Management
Wally Weitz
2.7%
BIO-TECHNE Corp's share of the portfolio
- Shares
- 543,200
- Value
- $38.4M
| Superinvestor | Weight | Value |
|---|---|---|
| Soros Fund Management | 0.5% | $37.8M |
Latest insider trades
See all insider tradesOpen-market purchases and sales by BIO-TECHNE Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 (view filing) | May 8 | 4 days | Herr Amy E.Director | SSale | −6.64K | $48.28 | −$320.4K | −97.1%200 after | |
| Feb 19, 2026 (view filing) | Feb 17 | 2 days | Herr Amy E.Director | SSale | −1.98K | $59.11 | −$116.8K | −90.8%200 after | |
| Aug 27, 2025 (view filing) | Aug 25 | 2 days | Nusse RoelandDirector | SSale | −17.0K | $56.36 | −$960.4K | −27.7%44.6K after | |
| Aug 27, 2025 (view filing) | Aug 25 | 2 days | Baumgartner Robert VDirector | SSale | −17.0K | $56.21 | −$957.8K | −27.5%44.9K after | |
| Jun 11, 2025 (view filing) | Jun 9 | 2 days | Herr Amy E.Director | SSale | −1.28K | $49.77 | −$63.7K | −39.3%1.98K after | |
| Feb 18, 2025 (view filing) | Feb 14 | 4 days | Herr Amy E.Director | SSale | −1.86K | $65.96 | −$122.7K | −48.5%1.98K after | |
| Jan 29, 2025 (view filing) | Jan 27 | 2 days | Kelderman KimChief Executive Officer | SSale | −13.4K | $77.28 | −$1.03M | −25.6%39.0K after | 2 lots |
| Aug 12, 2024 (view filing) | Aug 8 | 4 days | Baumgartner Robert VDirector | SSale | −16.0K | $72.10 | −$1.15M | −26.9%43.4K after | |
| May 16, 2024 (view filing) | May 14 | 2 days | Higgins John LDirector | SSale | −4.00K | $83.84 | −$335.4K | −9.9%36.6K after | |
| Mar 11, 2024 (view filing) | Mar 7 | 4 days | Nusse RoelandDirector | SSale | −10.4K | $76.98 | −$800.6K | −19.4%43.1K after |
Top 10 13F holders, Q2 2026
See all 601 holdersThe largest institutional positions in BIO-TECHNE Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 14,025,816 | $990.9M | 0.01% | +1,761,303+14.4% | Added |
| FMR LLC | 12,794,784 | $904.0M | 0.04% | +4,894,856+62.0% | Added |
| Vanguard Capital Management LLC | 10,218,558 | $721.9M | 0.02% | +38,849+0.4% | Added |
| Goldman Sachs Group Inc | 7,343,324 | $518.8M | 0.05% | +5,399,790+277.8% | Added |
| HBK Investments L P | 6,825,000 | $482.2M | 5.61% | +6,825,000 | New |
| Vanguard Portfolio Management LLC | 6,506,360 | $459.7M | 0.02% | +26,023+0.4% | Added |
| Morgan Stanley | 6,374,717 | $450.4M | 0.02% | −2,158,156−25.3% | Reduced |
| State Street Corp | 5,980,370 | $422.5M | 0.01% | +111,974+1.9% | Added |
| Geode Capital Management, LLC | 5,351,464 | $377.5M | 0.02% | +239,044+4.7% | Added |
| Invesco Ltd. | 4,986,424 | $352.3M | 0.03% | +397,718+8.7% | Added |
Holders of 5% or more of TECH
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of BIO-TECHNE Corp.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 13G | 7.38%11.6M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.00%11.0M shares | – | Oct 21, 20243 filings | Jul 16, 2025 | SEC |
Politician trades
All politician trades in TECH4 members of Congress reported 15 trades in BIO-TECHNE Corp since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| May 6, 2026 |  April McClain Delaney House · MD | Sell | $1K-$15K |
| Apr 6, 2026 | April McClain Delaney House · MD | Sell (partial) | $1K-$15K |
| Mar 10, 2026 | April McClain Delaney House · MD | Sell (partial) | $1K-$15K |
| Feb 2, 2026 | April McClain Delaney House · MD | Sell (partial) | $1K-$15K |
| Jan 5, 2026 | April McClain Delaney House · MD | Buy | $1K-$15K |
House · MD · May 6, 2026
Sell$1K-$15K
House · MD · Apr 6, 2026
Sell (partial)$1K-$15K
House · MD · Mar 10, 2026
Sell (partial)$1K-$15K
House · MD · Feb 2, 2026
Sell (partial)$1K-$15K
House · MD · Jan 5, 2026
Buy$1K-$15K